-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 G+RfBmK5DT8dTBMnwkEkgW6eTIlOMQHmZrbVPthjM5362I8iNUNntRZitt+/HLyS
 DJyUh80s4DehVyBkYaywJA==

<SEC-DOCUMENT>0000012208-10-000018.txt : 20100329
<SEC-HEADER>0000012208-10-000018.hdr.sgml : 20100329
<ACCEPTANCE-DATETIME>20100329161133
ACCESSION NUMBER:		0000012208-10-000018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100324
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100329
DATE AS OF CHANGE:		20100329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		10710838

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>b8k03292010.htm
<DESCRIPTION>FORM 8-K 03/29/2010
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES </TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="03/29/2010">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:672px"><P style="margin:0px; padding-top:4px; border-top:1px solid #000000" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:12pt" align=center><B>UNITED STATES </B></P>
<P style="margin:0px; font-size:12pt" align=center><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P style="margin:0px; font-size:12pt" align=center><B>WASHINGTON, D.C. 20549</B></P>
<P style="margin-top:10.667px; margin-bottom:0px; font-family:Times New Roman Bold; font-size:16pt" align=center><B>FORM 8-K</B></P>
<P style="margin-top:8px; margin-bottom:0px; padding-bottom:4px; border-bottom:1px solid #000000" align=center><BR></P>
<P style="margin-top:8px; margin-bottom:0px" align=center><BR></P>
<P style="margin-top:8px; margin-bottom:0px; font-size:12pt" align=center><B>CURRENT REPORT </B></P>
<P style="margin-top:8px; margin-bottom:0px" align=center><B>Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 </B></P>
<P style="margin-top:9.8px; margin-bottom:0px; font-size:11pt" align=center><B>Date of report: &nbsp;&nbsp;March 24, 2010 </B></P>
<P style="margin:0px" align=center>(Date of earliest event reported) </P>
<P style="margin:0px; padding-bottom:4px; border-bottom:1px solid #000000" align=center><BR></P>
<P style="margin-top:24px; margin-bottom:0px; font-size:18pt" align=center><B>BIO-RAD LABORATORIES, INC. </B></P>
<P style="margin:0px" align=center>(Exact name of registrant as specified in its charter) </P>
<P style="margin-top:0px; margin-bottom:16px; padding-bottom:4px; border-bottom:1px solid #000000" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:12pt" align=center><B>Commission File Number : 1-7928</B></P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD /><TD width=6.733 /><TD width=215.067 /><TD width=6.733 /><TD width=215.067 /></TR>
<TR><TD style="margin-top:0px"><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=6.733><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" width=215.067><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=6.733><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" width=215.067><P style="margin:0px; padding:0px">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=bottom><P style="margin:0px" align=center><B>Delaware</B></P>
</TD><TD style="margin-top:0px" valign=bottom width=6.733><P style="margin:0px; font-size:7.5pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=215.067><P style="margin:0px; padding:0px; font-size:12pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=6.733><P style="margin:0px; font-size:7.5pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=215.067><P style="margin:0px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=bottom><P style="margin:0px; font-size:7.5pt" align=center><B>(State or other jurisdiction of </B></P>
<P style="margin:0px; font-size:7.5pt" align=center><B>incorporation or organization)</B></P>
</TD><TD style="margin-top:0px" valign=bottom width=6.733><P style="margin:0px; font-size:7.5pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=215.067><P style="margin:0px; padding:0px; font-size:12pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=6.733><P style="margin:0px; font-size:7.5pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=215.067><P style="margin:0px; font-size:7.5pt" align=center><B>(IRS Employer </B></P>
<P style="margin:0px; font-size:7.5pt" align=center><B>Identification No.)</B></P>
</TD></TR>
</TABLE>
<P style="margin-top:16px; margin-bottom:0px" align=center><B>1000 Alfred Nobel Drive </B></P>
<P style="margin:0px" align=center><B>Hercules, California 94547</B></P>
<P style="margin:0px; font-size:7.5pt" align=center><B>(Address of principal executive offices) (Zip Code) </B></P>
<P style="margin-top:8px; margin-bottom:0px" align=center><B>(510) 724-7000 </B></P>
<P style="margin:0px; font-size:7.5pt" align=center><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P style="margin:0px; padding-bottom:4px; border-bottom:1px solid #000000" align=center><BR></P>
<P style="margin-top:24px; margin-bottom:0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P style="margin-top:0px; margin-bottom:1px; font-size:3pt">&nbsp;</P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=26.933 /><TD width=701.133 /></TR>
<TR><TD style="margin-top:0px" valign=top width=26.933><P style="margin:0px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top width=701.133><P style="margin:0px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P>
</TD></TR>
</TABLE>
<DIV style="width:672px"><P style="margin-top:0px; margin-bottom:4px; font-size:3pt">&nbsp;</P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=26.933 /><TD width=701.133 /></TR>
<TR><TD style="margin-top:0px" valign=top width=26.933><P style="margin:0px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top width=701.133><P style="margin:0px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P>
</TD></TR>
</TABLE>
<DIV style="width:672px"><P style="margin-top:0px; margin-bottom:4px; padding-right:-24px; font-size:3pt">&nbsp;</P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=26.933 /><TD width=701.133 /></TR>
<TR><TD style="margin-top:0px" valign=top width=26.933><P style="margin:0px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top width=701.133><P style="margin:0px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </P>
</TD></TR>
</TABLE>
<DIV style="width:672px"><P style="margin-top:0px; margin-bottom:4px; font-size:3pt">&nbsp;</P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=26.933 /><TD width=701.133 /></TR>
<TR><TD style="margin-top:0px" valign=top width=26.933><P style="margin:0px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top width=701.133><P style="margin:0px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </P>
</TD></TR>
</TABLE>
<DIV style="width:672px"><P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:14.667px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:14.667px; page-break-before:always"><BR></P>
<P style="margin-top:0px; margin-bottom:3.667px; font-family:CG Times (W1); font-size:11pt"><B>Item 5.02. &nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B>&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:11pt">On March 24, 2010, Bio-Rad Laboratories, Inc. (the &#147;Company&#148;) appointed Ted. W. Love, M.D. to its Board of Directors and as a member of the Board&#146;s audit committee. &nbsp;He replaced Mr. Ruediger Naumann-Etienne who resigned on December 4, 2009. &nbsp;Dr. Love will stand for election to the Board along with the Company&#146;s other directors at the Company&#146;s annual meeting of stockholders on April 27, 2010. &nbsp;There is no arrangement or understanding pursuant to which Dr. Love was appointed as director.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:11pt">On the same basis as the other non-employee directors of the Company, Dr. Love will be entitled to receive a fee of $2,000 per month plus an additional $100 per board meeting for any meetings in excess of 16 per year. &nbsp;In addition, Dr. Love will be entitled to receive an additional $625 per month for serving on the audit committee.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:11pt">As a result of Dr. Love&#146;s appointment, the Company regained compliance with the requirements of Section 303.A.07(a) of the New York Stock Exchange (&#147;NYSE&#148;) Listed Company Manual, which requires a listed company to have three independent directors on its audit committee. &nbsp;On March 25, 2010, the Company received written notice from the NYSE acknowledging that the Company is in compliance with all NYSE corporate governance listing standards. &nbsp;As a result, the &#147;BC&#148; or &#147;below compliance&#148; indicator, which was previously placed on the Company&#146;s ticker symbol subsequent to Mr. Naumann-Etienne&#146;s resignation, was removed on March 26, 2010. &nbsp;</P>
<P style="margin:0px; padding-bottom:4px; border-bottom:1px solid #000000"><BR></P>
<P style="margin:0px" align=center><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=83.333 /><TD width=492.667 /></TR>
<TR><TD style="margin-top:0px" valign=top width=83.333><P style="margin:0px; font-size:11pt"><B>ITEM 9.01</B></P>
</TD><TD style="margin-top:0px" valign=top width=492.667><P style="margin:0px; font-size:11pt"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=60 /><TD width=24 /><TD width=497.533 /></TR>
<TR><TD style="margin-top:0px" width=60><P style="margin:0px; font-size:11pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=24><P style="margin:0px; font-size:11pt">&nbsp;</P>
</TD><TD style="margin-top:0px" width=497.533><P style="margin:0px; font-size:11pt">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0px; border-bottom:1px solid #000000" valign=bottom width=60><P style="margin:0px; font-size:11pt"><B>Exhibit</B></P>
<P style="margin:0px; font-size:11pt"><B>Number&nbsp;</B></P>
</TD><TD style="margin-top:0px" valign=bottom width=24><P style="margin:0px; font-size:11pt">&nbsp;</P>
</TD><TD style="margin-top:0px; border-bottom:1px solid #000000" valign=bottom width=497.533><P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:11pt"><B>Description</B></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=60><P style="margin-top:2.467px; margin-bottom:0px; font-size:11pt" align=right>99.1&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=24><P style="margin-top:2.467px; margin-bottom:0px; font-size:11pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=497.533><P style="margin-top:2.467px; margin-bottom:0px; font-size:11pt">Press release of Bio-Rad Laboratories, Inc. dated March 25, 2010</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; font-size:11pt; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; font-size:11pt">&nbsp;</P>
<P style="margin:0px; font-size:11pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; font-size:11pt">&nbsp;&nbsp;</P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=50.867 /><TD width=136.333 /><TD width=29.467 /><TD width=29.467 /><TD width=4 /><TD width=301.867 /></TR>
<TR><TD style="margin-top:0px" valign=top width=50.867><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" width=136.333><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=305.867 colspan=2><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=50.867><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" width=136.333><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=305.867 colspan=2><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=50.867><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" width=136.333><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=335.333 colspan=3><P style="margin:0px; font-size:11pt">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=50.867><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" width=136.333><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=305.867 colspan=2><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=50.867><P style="margin:0px; font-size:11pt">Date:</P>
</TD><TD style="margin-top:0px; border-bottom:1px solid #000000" width=136.333><P style="margin:0px; font-size:11pt">&nbsp;&nbsp;&nbsp;March 29, 2010</P>
</TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; font-size:11pt">By:</P>
</TD><TD style="margin-top:0px; border-bottom:1px solid #000000" valign=bottom width=305.867 colspan=2><P style="margin:0px; font-size:11pt">/s/ Christine A. Tsingos</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=50.867><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=136.333><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=29.467><P style="margin:0px; font-size:11pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=4><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=301.867><P style="margin:0px; font-size:11pt">Christine A. Tsingos </P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=50.867><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=136.333><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=4><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=301.867><P style="margin:0px; font-size:11pt">Vice President, Chief Financial Officer</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=50.867><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=136.333><P style="margin:0px; font-size:11pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=29.467><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD><TD style="margin-top:0px" valign=bottom width=29.467><P style="margin:0px; font-size:11pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=4><P style="margin:0px; font-size:11pt">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=bottom width=301.867><P style="margin:0px; padding:0px; font-size:11pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 30C7B3CB -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Exhibit 99</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="03/29/2010">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:624px"><P style="margin:0px; padding-right:43.2px; font-family:Times New Roman Bold; font-size:11pt" align=right><B><U>Exhibit 99.1</U></B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv; font-size:11pt"><B>For Immediate Release</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv; font-size:11pt"><B>Bio-Rad Announces the Appointment of New Board Member</B></P>
<P style="margin:0px; font-family:Helv">Thursday March 25, 2010, 8:00 am EDT </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv"><B>HERCULES, CA--(Marketwire - 03/25/10)</B> --- Bio-Rad Laboratories, Inc. (NYSE:BIO - News) and (NYSE:BIO.B - News), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that Ted W. Love, M.D. has been appointed to its Board of Directors and will serve as a member of the Board's Audit Committee. As a result of this appointment, Bio-Rad has regained compliance with the New York Stock Exchange listing standard which requires a listed company to have three independent directors on its audit committee.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv">Dr. Love will stand for election to the Board along with Bio-Rad's other directors at the Company's annual meeting on April 27, 2010.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv">Dr. Love is currently Executive Vice President, Research and Development at Onyx Pharmaceuticals. From 2001 to 2009, he was President, Chief Executive Officer and member of the Board of Directors of Nuvelo, Inc. He served as chairman of Nuvelo's Board of Directors from 2005 to 2009. From 1998 to 2001, Dr. Love was Senior Vice President of Development at Theravance, Inc. From 1992 to 1998, he spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv">He is a member of the Board of Directors of Santarus, Inc., ARCA biopharma Inc., and Affymax, Inc. He also serves on the 29-member California Independent Citizen's Oversight Commission, which oversees the $3 billion dollars allocated to stem cell research authorized by California Proposition 71. Dr. Love holds an M.D. from Yale Medical School and a Bachelor of Arts degree from Haverford College.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv"><B>About Bio-Rad</B></P>
<P style="margin:0px; font-family:Helv">Bio-Rad Laboratories, Inc. (NYSE:BIO - News) and (NYSE:BIO.B - News) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit http://www.bio-rad.com/.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv; font-size:9pt"><I>This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, &quot;believe,&quot; &quot;expect,&quot; &quot;may,&quot; &quot;will,&quot; &quot;intend,&quot; &quot;estimate,&quot; &quot;continue,&quot; or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the &quot;Risk Factors&quot; in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Fo
rm 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.</I></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Helv">Contact:</P>
<P style="margin:0px; font-family:Helv">For more information, contact:</P>
<P style="margin:0px; font-family:Helv">Tina Cuccia, Corporate Communications Manager</P>
<P style="margin:0px; font-family:Helv">Bio-Rad Laboratories, Inc. </P>
<P style="margin:0px; font-family:Helv">510-724-7000 </P>
<P style="margin:0px; font-family:Helv">Email Contact &nbsp;&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 6DD747BC -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
